Tectonic Advisors LLC Has $10.40 Million Stock Holdings in Pfizer Inc. $PFE

Tectonic Advisors LLC increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 7.9% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 432,091 shares of the biopharmaceutical company’s stock after purchasing an additional 31,491 shares during the quarter. Tectonic Advisors LLC’s holdings in Pfizer were worth $10,405,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the stock. Brighton Jones LLC raised its holdings in shares of Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after acquiring an additional 618,117 shares during the period. Revolve Wealth Partners LLC boosted its stake in Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after purchasing an additional 2,087 shares during the period. United Bank boosted its stake in Pfizer by 12.4% in the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock worth $1,408,000 after purchasing an additional 6,415 shares during the period. Sei Investments Co. increased its holdings in Pfizer by 31.5% during the 2nd quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock worth $63,889,000 after purchasing an additional 631,523 shares in the last quarter. Finally, HUB Investment Partners LLC raised its stake in shares of Pfizer by 45.3% in the 2nd quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock valued at $2,480,000 after purchasing an additional 31,896 shares during the period. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Cantor Fitzgerald restated a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a report on Monday, July 6th. Royal Bank Of Canada raised Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price on the stock in a research report on Tuesday, June 9th. BMO Capital Markets cut their target price on Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research note on Monday, July 13th. Citigroup upped their price target on Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 29th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a research note on Wednesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Pfizer currently has a consensus rating of “Hold” and an average price target of $28.28.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer CEO Albert Bourla purchased approximately $1 million of company stock, adding 38,000 shares. The insider purchase may signal management’s confidence that the shares are undervalued. Pfizer CEO Buys $1 Million of Stock
• Positive Sentiment: Pfizer’s second-quarter results exceeded expectations, and management modestly raised 2026 revenue guidance to $60.5 billion-$62.5 billion. Analysts also highlighted stable core operations, strength from acquired brands and recent launches, and momentum in the non-COVID business. 5 Insightful Analyst Questions From Pfizer’s Q2 Earnings Call
• Positive Sentiment: Positive Phase 3 results for LITFULO in nonsegmental vitiligo strengthen Pfizer’s immunology pipeline and support the company’s effort to replace declining COVID-related revenue with newer products. Pfizer’s Higher 2026 Guidance and LITFULO Trial Results
• Positive Sentiment: Recent coverage points to growing investor interest in Pfizer’s launches, acquisitions and pipeline as potential drivers of longer-term growth, particularly from 2029 onward. Will Pfizer’s Non-COVID Portfolio Drive Its Next Phase of Growth?
• Neutral Sentiment: Analysts remain broadly focused on Pfizer’s valuation and earnings outlook; Erste Group raised its 2026 EPS estimate to $2.95 from $2.92, close to the approximately $2.98 consensus. Analysts Offer Insights on Healthcare Companies
• Negative Sentiment: Pfizer discontinued hemophilia gene therapy BEQVEZ as the commercial market contracts and physicians demand longer-term efficacy data, removing a potential growth contributor. Gene Therapy Remains Top-of-Mind in Hemophilia
• Negative Sentiment: Pfizer agreed to a $44 million class-action settlement related to Chantix safety-disclosure claims. The financial charge is manageable relative to Pfizer’s size but highlights continuing litigation exposure. Pfizer Agreed to a $44 Million Chantix Settlement
• Negative Sentiment: Arbutus filed additional patent-enforcement lawsuits against Pfizer and BioNTech concerning lipid nanoparticle technology, creating another potential legal overhang tied to COVID vaccine intellectual property. Arbutus Reports Second-Quarter Results

Pfizer Trading Up 1.9%

NYSE PFE opened at $26.80 on Friday. The company has a market cap of $152.77 billion, a PE ratio of 35.27 and a beta of 0.34. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 12 month low of $23.58 and a 12 month high of $28.75. The stock has a 50 day moving average of $25.11 and a 200-day moving average of $26.19.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the previous year, the company earned $0.78 earnings per share. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities research analysts anticipate that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.4%. Pfizer’s payout ratio is currently 226.32%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.